A Randomised Dose-Response Study of Prophylactic Methoxamine Infusion for Preventing Spinal-induced Hypotension during Cesarean Delivery

Feng Fu, Yu-Wen Tang, Hong Chen, Cuicui Jiao, Na Ma, Xinzhong Chen

TL;DR

Researchers have determined the optimal preventative infusion rates for methoxamine, a heart-friendly vasopressor, to combat the common problem of low blood pressure during spinal anesthesia for Cesarean sections. By testing four different dosages, the study established the effective doses required to prevent hypotension in 50% (ED50) and 95% (ED95) of patients, providing a precise clinical roadmap for safer obstetric anesthesia.

What Problem Does This Paper Address?

Spinal anesthesia is the gold standard for elective Cesarean delivery, but it comes with a nearly universal side effect: spinal-induced hypotension (SIH). When the anesthetic blocks nerves, blood vessels dilate, causing a sharp drop in maternal blood pressure. This isn't just uncomfortable for the mother (causing nausea and vomiting); it can also reduce blood flow to the placenta, potentially distressing the fetus.

While phenylephrine is currently the first-line drug used to counteract this, it can sometimes cause a reflexive slowing of the heart rate. This paper investigates methoxamine, a pure $\alpha_1$-adrenergic agonist. Methoxamine is intriguing because it can maintain blood pressure while actually reducing the heart's oxygen consumption—a significant advantage for maternal cardiac health. However, until now, the precise "sweet spot" for how much methoxamine to infuse preventatively (prophylactically) remained unclear.

Methods

The authors conducted a randomized, double-blind, dose-response study involving 80 parturients. This is a robust clinical design where neither the patients nor the doctors administering the drug knew the specific dosage being given.

Patients were split into four groups, receiving methoxamine at fixed rates based on their body weight:

  • Group M1: 1 μg/kg/min
  • Group M2: 2 μg/kg/min
  • Group M3: 3 μg/kg/min
  • Group M4: 4 μg/kg/min

The researchers defined an "adequate response" as the absence of hypotension (defined as systolic blood pressure dropping below 80% of the baseline). They then applied a probit regression model—a statistical tool commonly used to determine the relationship between a dose and a binary outcome—to calculate the ED50 and ED95 values.

Datasets

As a clinical trial, the "dataset" consisted of 80 healthy pregnant women (parturients) with singleton pregnancies scheduled for elective C-sections at the Women’s Hospital, Zhejiang University.

  • Inclusion criteria: ASA physical status $\leq$ 2, singleton pregnancy.
  • Exclusion criteria: Pre-existing hypertension, diabetes, cardiovascular disease, or a BMI > 30 kg/m².
  • Final Analysis: While 88 were initially assessed, 80 were randomized and completed the study (20 per group).

Key Insights and Ideas

  • Dose-Response Precision: The study successfully quantified the dose-response curve for methoxamine. The higher the dose, the lower the incidence of hypotension (75% in the low-dose group vs. only 10% in the high-dose group).
  • The "Goldilocks" Dose: The calculated ED95 of 4.821 μg/kg/min provides a concrete target for clinicians who want to ensure nearly all patients remain stable.
  • Neonatal Safety: Interestingly, the group receiving the lowest dose (M1) had the worst neonatal outcomes (lower Apgar scores and lower oxygen levels in umbilical blood). This suggests that the harm to the baby comes from the maternal hypotension itself, rather than the drug used to treat it.
  • Heart Rate Stability: Unlike some other vasopressors, methoxamine did not cause significant differences in the incidence of bradycardia (slow heart rate) across the different dosage groups in this study, supporting its profile as a heart-stable option.

Key Results

The quantitative findings provide clear benchmarks for obstetric anesthesia:

  • ED50: 2.178 μg/kg/min (95% CI: 1.564 to 2.680).
  • ED95: 4.821 μg/kg/min (95% CI: 3.951 to 7.017).
  • Hypotension Incidence: There was a significant linear trend ($P < 0.001$); as the dose increased from M1 to M4, the number of patients requiring "rescue" boluses of medication dropped significantly.
  • Hemodynamic Stability: Group M4 (the highest dose) showed the greatest stability in systolic blood pressure throughout the first 12 minutes following spinal anesthesia.

Limitations and Future Work

The authors identify several areas for further exploration:

  1. Short Observation Window: Hemodynamic data was only collected for the first 12 minutes. While this is the most critical window for SIH, later changes were not captured.
  2. Patient Population: The study focused on healthy patients. Results might differ for "high-risk" parturients (e.g., those with pre-eclampsia or twins).
  3. Lack of Cardiac Output Data: While blood pressure and heart rate were monitored, the study did not directly measure cardiac output or stroke volume, which would provide a more complete picture of the drug's effect on the heart.
  4. Comparison: Future studies could directly compare these optimized methoxamine doses against the current standard, phenylephrine, to see which truly offers superior maternal and fetal outcomes.

Summary updated

Abstract

Abstract Background: α-receptor agonists have been reported to be safe and effective for treating or preventing spinal-induced hypotension during cesarean delivery. As a pure α 1 adrenergic agonist, methoxamine has the advantage of reducing myocardial oxygen consumption and protecting the heart in obstetric patients compared to phenylephrine. Prophylactic infusion of vasopressor appears to be superior to bolus administration. The aim of this study was to determine the optimal prophylactic methoxamine infusion dose that would be effective for preventing spinal-induced hypotension in 50% (ED 50 ) and 95% (ED 95 ) of parturients. Methods : Eighty parturients with a singleton pregnancy scheduled for elective cesarean delivery were randomly allocated to receive prophylactic methoxamine infusion at one of four different fixed-rates: 1μg/kg/min (group M1), 2μg/kg/min (group M2), 3μg/kg/min (group M3), or 4μg/kg/min (group M4). An adequate response was defined as absence of hypotension (maternal SBP &lt;80% of baseline). The values for ED50 and ED95 of prophylactic methoxamine infusion were determined by probit regression model. The outcomes of maternal hemodynamics and fetal status were compared among the groups. Results: The calculated ED 50 and ED 95 (95% confidence interval) of prophylactic methoxamine infusion dose were 2.178 (95% CI 1.564 to 2.680) μg/kg/min and 4.821 (95% CI 3.951 to 7.017) μg/kg/min, respectively. The incidence of hypotension decreased with increasing methoxamine infusion dose (15/20, 11/20, 7/20 and 2/20 in group M1, M2, M3 and M4 respectively, P &lt; 0.001). 1-minute Apgar scores and umbilical arterial PaO2 were lower but umbilical arterial PaCO2 was higher in Group M1. No difference was found in the other incidence of adverse effects and neonatal outcomes among groups. Conclusions: Under the conditions of this study, when prophylactic methoxamine infusion was given at a fixed-rate based on body weight for preventing spinal-induced hypotension in obstetric patients, the values for ED 50 and ED 95 were 2.178μg/kg/min and 4.821μg/kg/min respectively.
BibTeX
@inproceedings{fu2020randomised,
  author = {Feng Fu and Yu-Wen Tang and Hong Chen and Cuicui Jiao and Na Ma and Xinzhong Chen},
  title = {{A Randomised Dose-Response Study of Prophylactic Methoxamine Infusion for Preventing Spinal-induced Hypotension during Cesarean Delivery}},
  booktitle = {Research Square},
  year = {2020},
  doi = {10.21203/rs.2.19385/v3},
}
Figure